Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Achieve Life Sciences Price Performance
ACHV stock traded up $0.12 during trading on Friday, hitting $2.57. The stock had a trading volume of 164,559 shares, compared to its average volume of 187,749. The company's 50-day moving average price is $2.56 and its two-hundred day moving average price is $3.45. Achieve Life Sciences has a twelve month low of $1.84 and a twelve month high of $5.59. The stock has a market capitalization of $89.14 million, a P/E ratio of -2.27 and a beta of 1.59. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78.
Insider Transactions at Achieve Life Sciences
In other Achieve Life Sciences news, CFO Mark K. Oki acquired 10,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $2.89 per share, with a total value of $28,900.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $28,900. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.00% of the company's stock.
Achieve Life Sciences Company Profile
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
